- Gossamer Bio will go public Friday on the Nasdaq.
- Shares priced at $16 apiece on Thursday evening, raising about $276 million.
- Gossamer will trade under the ticker “GOSS.”
Gossamer Bio priced its initial public offering on Thursday evening.
The clinical-stage biopharmaceutical company that focuses on “discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology” priced its IPO at $16 a share, according to a press release out Thursday evening. The sale of 17.25 million shares will raise about $276 million.
BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI were joint book-running managers for the offering.
Gossamer shares will trade on the Nasdaq, under the ticker “GOSS.”